Track Viridian Therapeutics, Inc. — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Viridian Therapeutics, Inc. VRDN · Stock Open Viridian Therapeutics, Inc. in new tab

19.31 USD
EPS
-3.35
P/B
3.93
ROE
-58.14
Beta
0.94
Target Price
36.13 USD
Loading chart...
Key Metrics
Earnings dateAug. 5, 2026
EPS-3.35
Book Value4.92
Price to Book3.93
Debt/Equity8.39
% Insiders0.137%
Growth
Revenue Growth0.96%
Estimates
Forward P/E-7.34
Forward EPS-2.63
Target Mean Price36.13

DCF Valuation

Tweak assumptions to recompute fair value for Viridian Therapeutics, Inc. (VRDN)
Currency: USD
DCF Assumptions
Decimal (e.g., 0.10 = 10%). Range allows declines (−50%) to strong growth (+50%).
Decimal (e.g., 0.30 = 30%).
Decimal (e.g., 0.04 = 4%).
Decimal (e.g., 0.20 = 20%).
Percent number (e.g., 3 = 3%).
Percent number (e.g., 10 = 10%).
Percent number (e.g., 5 = 5%).
DCF Result

Fair Value (DCF)
Current Price
Upside
WACC
Terminal PV
Σ PV of FCFs
Note: historical bars show reported FCF (for context); forward bars show PV of projected FCF; if no per-year data, totals are shown.

Viridian Therapeutics, Inc. Logo Viridian Therapeutics, Inc. Analysis (VRDN)

United States Health Care Official Website Stock

Is Viridian Therapeutics, Inc. a good investment? Viridian Therapeutics, Inc. (VRDN) is currently trading at 19.31 USD. Market analysts have a consensus price target of 36.13 USD. This suggests a potential upside from current levels.

Earnings Schedule: Viridian Therapeutics, Inc. is expected to release its next earnings report on Aug. 5, 2026. The market consensus estimate for Forward EPS is -2.63.

Investor FAQ

Does Viridian Therapeutics, Inc. pay a dividend?

No, it does not currently pay a dividend.

What asset class is Viridian Therapeutics, Inc.?

Viridian Therapeutics, Inc. is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.

When is the next earnings date?

The next earnings date is projected to be Aug. 5, 2026. The company currently has a trailing EPS of -3.35.

Company Profile

Viridian Therapeutics, Inc. engages in discovering, developing, and commercializing treatments for serious and rare diseases. It develops IGF-1R therapies to treat thyroid eye disease (TED), including Veligrotrug, a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered, and Elegrobart, a low-volume, infrequently dosed subcutaneous IGF-1R. The company also develops an anti-thyroid-stimulating hormone receptor (TSHR) candidate for the treatment of Graves' disease and TED. Its portfolio of engineered inhibitors of the neonatal Fc receptor (FcFn) includes VRDN-006, a highly selective Fc fragment, and VRDN-008, a half-life extended bispecific FcRn inhibitor comprising an GC fragment and an albumin-binding domain designed to prolong IGG suppression. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021. Viridian Therapeutics, Inc. was incorporated in 2010 and is headquartered in Waltham, Massachusetts.

Exchange Ticker
NMS (United States) VRDN
Trades
Dividend History paid per year (USD)
No dividend history available.
Stock Splits
Split Date Split Ratio to 1
Nov. 7, 2016 0.070000
Nov. 13, 2020 0.070000
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion